In an interview with Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses the changing role of PBMs and recent price structure overhauls.
The Evolving Role of PBMs: An Interview with Bill Roth, General Manager, Managing Partner, Blue Fin Group
You May Also Like
Global Launch Strategies in the Current Political Climate
February 19, 2025
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 19, 2025
Navigating Distrust: Pharma in the Age of Social Media
February 18, 2025
+ There are no comments
Add yours